NCT03980730

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

Randomized, Double-blind, Placebo-controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects With Mild Alzheimer's Disease and Impaired Glucose Tolerance

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: vTv Therapeutics · Industry
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	Azeliragon	Azeliragon 5 mg capsule administered orally, once daily
DRUG	Placebo	Matching placebo capsule administered orally, once daily

Timeline

• Start date: 2019-06-27
• Primary completion: 2020-12-01
• Completion: 2021-01-29
• First posted: 2019-06-10
• Last updated: 2022-01-21
• Results posted: 2022-01-21

Locations

33 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study